Summary Nephrotoxicity is a significant problem in children after treatment with ifosfamide. Acute changes in renal function were compared in 16 children receiving 9 g m-2 of ifosfamide as a 72-h continuous infusion on one occasion and, on another course, divided into three 1 -h infusions on consecutive days. Subclinical acute nephrotoxicity was demonstrated with both schedules, but there were no significant differences in severity.
Subclinical renal damage has been reported in most children treated with ifosfamide (Skinner et al, 1990; Heney et al, 1991) , and in some series between 20% and 40% of children have required some form of mineral replacement therapy because of inappropriate renal tubular loss of phosphate and bicarbonate (Skinner et al, 1990; Caron et al, 1992; De Schepper et al, 1993) . Renal failure may occur acutely and prevent the delivery of planned chemotherapy, however it is more often a chronic problem with severely affected children suffering from hypophosphataemic rickets, renal tubular acidosis and occasionally nephrogenic diabetes insipidus. Impairment of growth may result from renal tubular acidosis and rickets (De Schepper et al, 1991; Rossi et al, 1992; Skinner et al, 1992) . Higher cumulative dose of ifosfamide, younger patient age at treatment (Suarez et al, 1991; Skinner et al, 1992; Al Sheyyab et al, 1993; De Schepper et al, 1993) , prior nephrectomy and pre-existing renal impairment, including that caused by prior or concomitant treatment with cisplatin, have all been reported as being associated with an increased risk of ifosfamide-induced nephropathy (Pratt et al, 1991; Suarez et al, 1991; Caron et al, 1992; Skinner et al, 1992; Al Sheyyab et al, 1993; De Schepper et al, 1993) , Marina et al, 1993; Tournade, 1993; Rossi et al, 1994a,b) .
A further possible risk factor is the method of administration of the drug. Schedules of administration in children have varied from short infusions over 15 min to continuous infusion over 3 or more days. One study in adults reported less nephrotoxicity after continuous infusion rather than bolus administration of ifosfamide, but the differences were not statistically significant (Antman et al, 1989) . Nephrotoxicity has been documented after all schedules of ifosfamide, and a detailed review found no clear evidence that any schedule showed a significant difference in nephrotoxicity (Skinner et al, 1993) . Although both acute and chronic changes have been shown after the administration of ifosfamide, so far there have been no reports of longitudinal studies relating the two.
Ifosfamide is a prodrug that metabolized in the liver by the cytochrome P-450 system, and administration by a short infusion may saturate metabolizing capacity, which would provide an explanation for different toxicities between schedules. This report describes a comparison of the acute changes in renal function seen after the administration of 6 or 9 g m-2 ifosfamide as a continuous infusion (CI) over 72 h or divided into three 1-h infusions (SI) on consecutive days. 3 g m-2 mesna were administered each day. In addition, when ifosfamide was infused over 1 h, a bolus of 1.2 g m-2 mesna was given at the start of treatment on day 1, and those receiving ifosfamide by continuous infusion had an additional 12 h of intravenous hydration with 1.5 g m-2 mesna in the hydration fluid after the ifosfamide finished. Patient 4 received only 6 g m-2 ifosfamide per course over 3 days, and the mesna dose was reduced by an equivalent amount. Other cytotoxic drugs that the patients received included etoposide or vincristine and doxorubicin or vincristine and actinomycin.
METHODS

Measures of nephrotoxicity
We have previously described a protocol to assess glomerular and proximal and distal renal tubular function (Skinner et al, 1991) . Serum creatinine (S Creat) was used because of the practical and ethical difficulties of performing three plasma [51Cr]EDTA clearances within 3 weeks to assess glomerular function when not clinically necessary. Proximal renal tubular function was assessed by measuring serum carbon dioxide (SCO2), the renal tubular threshold for phosphate (TmpIGFR), fractional excretion of glucose (FE gluc) and the urine retinol binding protein to urine creatinine ratio (URBP:C). Distal renal tubular function was assessed by changes in urine pH and osmolality (U osmo). Global renal tubular function was assessed by measuring the ratios of the urine concentrations of the following-substances to urine creatinine: protein (UProt:C), retinol binding protein (URBP:C), alkaline phosphatase (UALP:C), alanine aminopeptidase (UAAP:C), lactic dehydrogenase (ULDH:C) and N-acetylglucoseaminidase (UNAG:C). These measurements were performed before and at 1 and 18 days after completing chemotherapy.
Analysis of results
Changes in renal function after CI and SI at I or 18 days after completion of chemotherapy were compared with the pretreatment results. Wilcoxon's signed-rank test was used to test the significance of the changes seen after each schedule. The patients were divided into two groups, those who had received the CI before the SI and those who had received the SI before the CI. A 2 x 2 crossover analysis was performed and the groups were examined for evidence of (1) 
RESULTS
Early changes 1 day after treatment
These results are shown in Table 2 . There were significant falls in the SCO2 and Tmp/GFR and significant rises in the FE gluc, the urine pH, the UNAG:C, ULDH:C and UProt:C after both the CI and the SI. There was a significant rise after the CI schedule but not the SI schedule for the UAAP:C. There were significant rises after the SI but not the CI schedule for UALP:C and URBP:C. There was a significant reduction in the S creat after the CI but not after the SI. There was a significant fall in U osmo after both schedules; this is to be expected because of the hydration regimen and is not reported.
Late changes 18 days after treatment
The above changes had largely resolved 18 days after completion of treatment, and the only significant differences were elevations seen in FE gluc (P = 0.01), URBP:C (P = 0.03 1) and UNAG:C (P = 0.046) after the CI but not after the SI and a reduction in the serum carbon dioxide after the SI (P = 0.021) but not the CI.
Comparison between schedules
No significant treatment effect, period effect or treatment-period interaction was demonstrated for either the SI or the CI. As shown in Table 2 , both schedules had very similar effects on measures of subclinical nephrotoxicity. The small numbers in this study mean that the power of detecting an important difference in the parameters measured is low. For example, the power of detecting a 25% difference in Tm /GFR between the two schedules at a-level 0.05 p is only 44%. Based on the differences seen over the first two courses of treatment in the patients in the prospective study, 96 subjects undergoing paired studies would be required to detect this with a power of 80%.
DISCUSSION
The administration of ifosfamide either as a CI or a SI caused significant short-term changes in renal function. This was most striking for the SCO2, Tm/GFR, UNAG:C, ULDH:C, UProt:C and FE gluc. There were no important changes in the S creat after either schedule. The FE gluc, URBP:C and UNAG:C were still elevated 21 days after the CI, and the SCO2 was lower 21 days after the SI. Using a crossover analysis, there was no significant difference in the nephrotoxicity observed when ifosfamide was administered either as a continuous infusion or three separate 1-h infusions.
It is now apparent that both schedules cause significant changes in measures of subclinical renal damage. Considerably larger numbers of patients would need to be entered into a study to have sufficient power to confirm a statistically significant difference between the schedules, however the similarity of the changes after the CI and the SI suggest that clinically important differences are unlikely. It is known that ifosfamide causes cumulative damage (Heney et al, 1991; Caron et al, 1992; Al Sheyyab et al, 1993) which could confound the results, however the cumulative dose before each schedule was very similar and no treatment-period interaction was demonstrated, although again the numbers are small.
Both RBP and B2 microglobulin have been found to be sensitive measures of ifosfamide-induced renal tubular damage (Al Sheyyab et al, 1993; De Schepper et al, 1993) . Some patients were already on treatment when this study started and had already received large cumulative doses of ifosfamide. These heavily pretreated patients demonstrated abnormalities in the baseline studies especially in the URBP:C. This pre-existing damage may explain why this very sensitive test was not a more discriminating test for acute renal damage between the ifosfamide schedules that were studied. Ifosfamide is a prodriug and it is thought that its nephrotoxic metabolites may include chloracetaldehyde which is produced in equimolar quantities with the dechlorethylated metabolites (Skinner et al, 1993) . The patients reported in this paper have all had pharmacokinetic and metabolic studies of ifosfamide performed. These have been reported as studies of ifosfamide administered as a continuous infusion (Boddy et al, 1993) and studies of intra-individual variation in metabolism (Boddy et al, 1994) . A comparison of the metabolism of ifosfamide administered either as short or as continuous infusions showed that there was a trend for reduced production of dechlorethylated metabolites following short infusions (Boddy et al, 1995) . A negative correlation between the production of dechlorethylated metabolites over 6 months during ifosfamide treatment and renal damage 1 and 6 months after the completion of treatment has been observed (Boddy et al, 1996) . This study also observed no significant difference in nephrotoxicity between ifosfamide administered as a SI or a CI. There is overlap between 12 patients in that study and those reported in the present study. The comparisons of nephrotoxicity between SI and CI were made between courses when pharmacokinetic studies were performed, and these could be separated by several other courses of treatment. Therefore the hypothesis that ifosfamide schedule is related to nephrotoxicity was tested separately and is reported in the current paper.
The present study examined acute changes in renal function following the administration of ifosfamide. There is evidence that renal damage occurs early on in treatment with ifosfamide and is progressive (Heney et al, 1991; Caron et al, 1992; Al Sheyyab et al, 1993) , but acute changes in renal function following one course of treatment have not yet been related to long-term renal damage. This study compares the nephrotoxicity of different schedules of ifosfamide in the same patients. In a phase II study in adults, the schedule of ifosfamide was changed from 2 g m-2 over 4 h on four consecutive days to 8 g m-2 by continuous infusion over 4 days in an attempt to reduce toxicity (Antman et al, 1989 between the schedules. The small number of subjects means that there is the possibility of a 1-error and that there really is a statistically significant difference between the schedules, however the evidence presented here suggests that this is unlikely to be of clinical importance. Future studies using ifosfamide should investigate reducing the total dose of ifosfamide and trying to predict those at increased risk of ifosfamide-induced renal damage. If scheduling of the drug is altered in an attempt to reduce toxicity then it should be done in a prospective, randomized trial that includes both toxicity and efficacy after treatment as end points.
